CBFB and acute myeloid leukemia: Although the cumulative incidence of morphologic relapse at three years was similar between patients with RUNX1::RUNX1T1, CBFB::MYH11, and NPM1-mutated AML (18% [8–28%], 16% [8–24%], and 19% [13–25%], respectively), the cumulative incidence of molecular relapse was lower in patients with RUNX1::RUNX1T1 AML (23% [12–34%], 31% [21–41%], and 34% [27–42%], respectively); Supplementary Fig. 1).